AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
Log in

NASDAQ:AVROAvrobio Stock Price, Forecast & News

$20.22
+1.04 (+5.42 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$18.82
Now: $20.22
$20.44
50-Day Range
$12.51
MA: $14.94
$20.61
52-Week Range
$9.76
Now: $20.22
$29.32
Volume315,604 shs
Average Volume335,964 shs
Market Capitalization$728.63 million
P/E RatioN/A
Dividend YieldN/A
Beta1.49
AVROBIO, Inc., a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease. The company's lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02 that has completed pre-clinical trials for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; and AVR-RD-04 that has completed pre-clinical studies for treating cystinosis. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Read More
Avrobio logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.45 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AVRO
CUSIPN/A
CIKN/A
Phone617-914-8420

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$7.12 per share

Profitability

Net Income$-72,960,000.00

Miscellaneous

Employees49
Market Cap$728.63 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive AVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVRO and its competitors with MarketBeat's FREE daily newsletter.

Avrobio (NASDAQ:AVRO) Frequently Asked Questions

How has Avrobio's stock been impacted by COVID-19 (Coronavirus)?

Avrobio's stock was trading at $18.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AVRO stock has increased by 12.2% and is now trading at $20.22. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Avrobio?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avrobio in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Avrobio.

When is Avrobio's next earnings date?

Avrobio is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Avrobio.

How were Avrobio's earnings last quarter?

Avrobio Inc (NASDAQ:AVRO) released its quarterly earnings results on Thursday, May, 7th. The company reported ($0.77) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.66) by $0.11. View Avrobio's earnings history.

What price target have analysts set for AVRO?

7 brokerages have issued 12-month target prices for Avrobio's stock. Their forecasts range from $13.00 to $43.00. On average, they anticipate Avrobio's stock price to reach $33.60 in the next year. This suggests a possible upside of 66.2% from the stock's current price. View analysts' price targets for Avrobio.

Has Avrobio been receiving favorable news coverage?

Media coverage about AVRO stock has been trending somewhat positive on Friday, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Avrobio earned a news sentiment score of 0.6 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View the latest news aboutAvrobio.

Are investors shorting Avrobio?

Avrobio saw a decrease in short interest in May. As of May 15th, there was short interest totaling 1,340,000 shares, a decrease of 26.4% from the April 30th total of 1,820,000 shares. Based on an average trading volume of 388,200 shares, the short-interest ratio is currently 3.5 days. Currently, 4.7% of the company's shares are short sold. View Avrobio's Current Options Chain.

Who are some of Avrobio's key competitors?

What other stocks do shareholders of Avrobio own?

Who are Avrobio's key executives?

Avrobio's management team includes the following people:
  • Mr. Geoff MacKay, Co- Founder, Pres, CEO & Director (Age 53)
  • Mr. Steven N. Avruch, VP, Gen. Counsel & Sec. (Age 58)
  • Mr. Jeffrey Medin Ph.D., Scientific Founder
  • Mr. Erik Ostrowski, CFO & Treasurer (Age 46)
  • Dr. Kim Warren, Head of Operations

When did Avrobio IPO?

(AVRO) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities served as the underwriters for the IPO and Wedbush Securities was co-manager.

What is Avrobio's stock symbol?

Avrobio trades on the NASDAQ under the ticker symbol "AVRO."

Who are Avrobio's major shareholders?

Avrobio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (7.19%), BlackRock Inc. (5.43%), Eventide Asset Management LLC (5.29%), Camber Capital Management LP (3.75%), Aisling Capital Management LP (2.80%) and Wellington Management Group LLP (2.46%). Company insiders that own Avrobio stock include Bruce Booth, Christopher Paige and Geoffrey Mackay. View institutional ownership trends for Avrobio.

Which institutional investors are selling Avrobio stock?

AVRO stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, BNP Paribas Arbitrage SA, Squarepoint Ops LLC, and Virtus ETF Advisers LLC. Company insiders that have sold Avrobio company stock in the last year include Christopher Paige, and Geoffrey Mackay. View insider buying and selling activity for Avrobio.

Which institutional investors are buying Avrobio stock?

AVRO stock was purchased by a variety of institutional investors in the last quarter, including Camber Capital Management LP, Vivo Capital LLC, Wellington Management Group LLP, Eventide Asset Management LLC, JPMorgan Chase & Co., Driehaus Capital Management LLC, Burrage Capital Management LLC, and UBS Group AG. View insider buying and selling activity for Avrobio.

How do I buy shares of Avrobio?

Shares of AVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Avrobio's stock price today?

One share of AVRO stock can currently be purchased for approximately $20.22.

How big of a company is Avrobio?

Avrobio has a market capitalization of $728.63 million. The company earns $-72,960,000.00 in net income (profit) each year or ($2.66) on an earnings per share basis. Avrobio employs 49 workers across the globe.

What is Avrobio's official website?

The official website for Avrobio is www.avrobio.com.

How can I contact Avrobio?

Avrobio's mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-914-8420 or via email at [email protected]

This page was last updated on 5/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.